SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Chemicals and Pharmaceuticals Ltd on Wednesday announced that it has received approvals from the US Food and Drug Administration for its anti-infection drug Piperacillin-Tazobactam, in injectible form.

 

These approvals cover Orchid’s generic equivalents in 2.25 g, 3.375 g and 4.5 g vial as well as 40.5 g (pharmacy bulk package) dosage forms and strengths. The US FDA determined that Orchid is a ‘first applicant’ for the products and granted 180-day generic drug exclusivity. Orchid will launch these products in marketing and distribution partnership with Apotex in the US.crackcrack

Orchid Pharma Share Price

548.55 -10.65 (-1.90%)
13-Apr-2026 09:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1643.10
Dr. Reddys Lab 1212.80
Cipla 1208.00
Zydus Lifesciences 905.85
Lupin 2314.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×